51372 Barzolvolimab demonstrates safety and clinically meaningful activity as early as two weeks in moderate to severe prurigo nodularis - 01/09/24
Doi : 10.1016/j.jaad.2024.07.562
Sonja Stander, MD
Center for Chronic Pruritus (Kompetenzzentrum Chronischer Pruritus; KCP)
Department of Dermatology, Münster University Hospital, Münster, Germany
Ali Moiin, MD
Revival Research Institute LLC, Troy, Michigan, USA
Wayne State University School of Medicine, Detroit, MI, USA
Leigh Nattkemper, MD
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, Miller School of Medicine, University of Miami, Miami, Florida, USA
Yufang Lu, MD, PhD
Celldex Therapeutics, Hampton, New Jersey, USA
Current employee of Inmagene Biopharmaceuticals, San Diego, California, USA
Marcus Maurer, MD
Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Gil Yosipovitch, MD
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, Miller School of Medicine, University of Miami, Miami, Florida, USA
Il testo completo di questo articolo è disponibile in PDF.
| Commercial Support: 100% sponsored by Celldex Therapeutics. |
© 2024
Pubblicato da Elsevier Masson SAS.
Vol 91 - N° 3S
P. AB140 - settembre 2024 Ritorno al numero
Articolo precedente
- 53991 Barriers to Home Injection of Biologics
- Ana Duarte-Summers, Georgette Hattier, Elizabeth Jones
- 53575 BASAL CELL CARCINOMA IN THE POPULATION OF THE ECUADORIAN AMAZON
- Doménica Anahí Palacios Segarra, Gabriela de los Ángeles Criollo Jaramillo, Nathaly Paola Lascano Gallegos, Santiago Alberto Palacios Álvarez
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?